The efficacy of non-thermal gas plasma in the treatment of diabetic foot ulcers stalled by subclinical, biofilm-related wound infection
Cornelia Wiegand, Laura Rudkte, Keith Cutting, Jeiram Jeyaratnam, Mary McGovern, Paul Chadwick, Samantha Haycocks, David Russell, Nikki Dewhirst, Janet Woods, Steven Jeffery
Cornelia Wiegand is Head of Laboratory, Department of Dermatology, University Hospital Jena, Germany
Laura Rudtke is Medical PhD Student, Department of Dermatology, University Hospital Jena, Germany
Keith Cutting is Clinical Research Consultant, Health Directions, Hertfordshire, UK
Jeiram Jeyaratnam is Business Development Manager, Adtec Europe Ltd, Twickenham, UK
Mary McGovern is Managing Director, Adtec Europe Ltd, Twickenham, UK
Paul Chadwick is Clinical Director The Royal College of Podiatry and Visiting Professor Birmingham City University, Birmingham, UK
Samantha Haycocks is Research Nurse, Podiatry Department, Salford Royal NHS Foundation Trust, Salford, UK
David Russell is Associate Professor, Leeds Institute for Clinical Trials Research, University of Leeds and Honorary Consultant Vascular Surgeon, Diabetes Limb Salvage Service / Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Nikki Dewhirst is Senior Vascular Research Nurse, Diabetes Limb Salvage Service/Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Janet Woods is Vascular Research Nurse, Diabetes Limb Salvage Service / Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Steven Jeffery is Consultant Plastic Surgeon and Professor of wound study, Birmingham City University, Birmingham, UK
Wounds International, Vol 13 Issue 4 Dec. 2022
Related Publications
Advanced Therapies
Advanced Therapies
MolecuLight Headquarters
425 University Avenue Suite 700 Toronto, ON M5G 1T6 Canada
US Address MolecuLight Corp. 2403 Sidney Street, Suite 286 Pittsburgh, PA 15203
T. 1-877-818-4360
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.